NCT07503353 2026-03-31
A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies
Sheba Medical Center
Phase 1/2 Not yet recruiting
Clinical Trials
8 trialsNCT07135466 2026-01-16
A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
Sheba Medical Center
Phase 1/2 Recruiting
NCT06299462 2025-02-25
PTCy and ATG for MSD and MUD Transplants
Instituto Nacional de Cancer, Brazil
Phase 1/2 Recruiting
NCT05429905 2023-03-09
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
KK Women's and Children's Hospital
Phase 1/2 Unknown
NCT05149339 2021-12-08
Vitamin D Effect on A Disintegrin-like And Metalloprotease Thrombospondin1 Motif 13& Interleukin 6 in Leukemia
Zagazig University
Phase 1/2 Completed
NCT02772198 2020-11-03
T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies
Sheba Medical Center
Phase 1/2 Unknown
NCT03040401 2017-12-19
A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)
Vastra Gotaland Region
Phase 1/2 Unknown
NCT02115672 2016-08-15
Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia
Sheba Medical Center
Phase 1/2 Withdrawn